Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
3 Ro5 violations · MW 1,449.27 Da
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | < 10 % | Reported | PepTherDia curated product PK field | Route: ORAL · 80 · Vancomycin · exact product name match · exact or normalized match | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 78800 ng*h/mL | Comparable | Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats · rat | Route: iv · area under curve · AUC· Area under the curve measured after intravenous bolus administrat... | Open |
| 2 | 13715 ng*h/mL | Comparable | AUC (0 to 24 hrs) in ICR mouse plasma at 10 mg/kg, iv by LC-MS/MS analysis · mouse · plasma | Route: iv · area under curve · AUC· AUC (0 to 24 hrs) in ICR mouse plasma at 10 mg/kg, iv by LC-MS/MS... | Open |
| 3 | 1271 ng*h/mL | Comparable | AUC (infinity) in CD1 mouse at 5 mg/kg, iv · mouse | Route: iv · area under curve · AUC· AUC (infinity) in CD1 mouse at 5 mg/kg, iv · Exact ChEMBL pref na... | Open |
| 4 | 358600 ng*h/mL | Comparable | AUC in human at 1 g, iv administered every 12 hrs · human | Route: iv · area under curve · AUC· AUC in human at 1 g, iv administered every 12 hrs · Exact ChEMBL... | Open |
| 5 | 358600 ng*h/mL | Comparable | AUC in human serum at 1 g, iv administered every 12 hrs · human · serum | Route: iv · area under curve · AUC· AUC in human serum at 1 g, iv administered every 12 hrs · Exact C... | Open |
| 6 | 298800 ng*h/mL | Comparable | AUC in rabbit at 1 g, iv administered twice daily · rabbit | Route: iv · area under curve · AUC· AUC in rabbit at 1 g, iv administered twice daily · Exact ChEMBL... | Open |
| 7 | 101000 ng*h/mL | Comparable | AUC in rabbit at 25 mg/kg, iv · rabbit | Route: iv · area under curve · AUC· AUC in rabbit at 25 mg/kg, iv · Exact ChEMBL pref name VANCOMYCIN... | Open |
| 8 | 1242 ng*h/mL | Comparable | AUClast in CD1 mouse at 5 mg/kg, iv · mouse | Route: iv · area under curve · AUC· AUClast in CD1 mouse at 5 mg/kg, iv · Exact ChEMBL pref name VANC... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 44160.16 nM | Comparable | Cmax in healthy human male at 1000 mg, iv every 12 hrs by LC/MS/MS analysis · human | Route: iv · max concentration · Cmax· Cmax in healthy human male at 1000 mg, iv every 12 hrs by LC/MS... | Open |
| 2 | 35880.13 nM | Comparable | Cmax in human at 1 g, iv administered every 12 hrs · human | Route: iv · max concentration · Cmax· Cmax in human at 1 g, iv administered every 12 hrs · Exact ChEM... | Open |
| 3 | 35880.13 nM | Comparable | Cmax in human serum at 1 g, iv administered every 12 hrs · human · serum | Route: iv · max concentration · Cmax· Cmax in human serum at 1 g, iv administered every 12 hrs · Exac... | Open |
| 4 | 40365.15 nM | Comparable | Cmax in ICR mouse plasma at 10 mg/kg, iv measured after 20 mins by LC-MS/MS analysis · mouse · plasma | Route: iv · max concentration · Cmax· Cmax in ICR mouse plasma at 10 mg/kg, iv measured after 20 mins... | Open |
| 5 | 31740.12 nM | Comparable | Cmax in rabbit at 1 g, iv administered twice daily · rabbit | Route: iv · max concentration · Cmax· Cmax in rabbit at 1 g, iv administered twice daily · Exact ChEM... | Open |
| 6 | ~ 63 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: intravenous · Vancomycin· 12.3 Pharmacokinetics · vancomycin iv infusion completion cmax 60min · 12.3 P... | Open |
| 7 | ~ 49 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Vancomycin· 12.3 Pharmacokinetics · vancomycin iv infusion completion cmax 30min · Multip... | Open |
| 8 | 111780.41 nM | Comparable | Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats · rat · plasma | Route: iv · max concentration · Cmax· Maximum plasma concentration measured after intravenous bolus a... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 60 min 3600 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: intravenous · Vancomycin· 12.3 Pharmacokinetics · vancomycin iv infusion completion tmax 60min · 12.3 P... | Open |
| 2 | 30 min 1800 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Vancomycin· 12.3 Pharmacokinetics · vancomycin iv infusion completion tmax 30min · Multip... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.3093 L/kg | Comparable | Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats · rat | Route: iv · volume of distribution · Vdss· Volume of distribution at a steady state measured after in... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 55 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Vancomycin· 12.3 Pharmacokinetics · vancomycin serum protein binding ultrafiltration · Va... | Open |
| 2 | 50 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: IV, ORAL · 80 · Vancomycin · exact product name match · exact or normalized match | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 10.7 mL/min/kg | Comparable | Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats · rat | Route: iv · clearance · CL· Clearance measured after intravenous bolus administration of 50 mg/kg of... | Open |
| 2 | ~ 0.058 L/kg/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Vancomycin· 12.3 Pharmacokinetics · vancomycin mean plasma clearance · Elimination Mean p... | Open |
| 3 | ~ 0.048 L/kg/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Vancomycin· 12.3 Pharmacokinetics · vancomycin mean renal clearance · Elimination Mean pl... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | DistributionExposurePersistence Clearance, Max Concentration, Plasma Protein Binding, Time To Max Concentration | No reported alias | 0 identity 7 evidence |
PubMed 17485502 | Exposure Area Under Curve, Max Concentration | No reported alias | 0 identity 5 evidence |
PubMed 14584952 | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Volume Of Distribution | No reported alias | 0 identity 4 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias | 1 identity 2 evidence |
PubMed 18426900 | Exposure Area Under Curve, Max Concentration | No reported alias | 0 identity 2 evidence |
PubMed 27994762 | Exposure Area Under Curve, Max Concentration | No reported alias | 0 identity 2 evidence |
PubMed 29243921 | Exposure Area Under Curve | No reported alias | 0 identity 2 evidence |
PubMed 19349514 | Exposure Max Concentration | No reported alias | 0 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0035831' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.